

## **GenoMed's Free Medical Advice™ Campaign: The Toast of Italy**

FOR IMMEDIATE RELEASE

Contact:

David W. Moskowitz MD

CEO, GenoMed

Tel. 314.983.9933

[dwmoskowitz@genomed.com](mailto:dwmoskowitz@genomed.com)

Skype ID: dwmoskowitz

ST. LOUIS—March 13, 2009—GenoMed® (OTC Pink Sheets GMED.PK) announced today that Technical Medical Improvement (TMI), an Italian company, is featuring GenoMed's Free Medical Advice™ campaign on its website ([http://www.technicalmedical.com/en/tmi\\_news.html](http://www.technicalmedical.com/en/tmi_news.html)).

Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, "The Internet has made the world a tiny place. We appreciate that our friends in Italy are paying attention to us. That means people in our own country may not be too far behind."

About TMI

TMI is a leader in defining and developing new training tools and training systems in a variety of fields-with a particular focus on healthcare, social systems, education and emergency management. TMI operates within Italy and world-wide by providing products and services in the following areas:

- Advanced Medical Training
- Healthcare Communication
- Marketing Solutions
- Research & Development

Expert in dealing with institutions, pharmaceutical companies, medical personnel and research centers, TMI aims to become top-level contact in the promotion and management of high profile scientific programs.

About GenoMed

GenoMed ([www.genomed.com](http://www.genomed.com)) published how to prevent 90% of kidney failure, and how to retard the progression of emphysema (COPD) in 2002. The company's "recipes" are the subject of pending patents in the US. Two patents have been awarded: one for treating acute kidney failure without dialysis, and a second for hastening lung maturation in premature infants.

Safe Harbor Statement

This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to our research and development being subject to scientific, economic, regulatory, governmental, and technological factors, and the possibility of our not being able to field all the calls and emails we receive. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.